Forte Biosciences, Inc. — Form 8-K

Forte's FB102 (anti-CD122 monoclonal antibody) achieved 29.6% mean FVASI improvement from baseline at week 24 versus 7.9% for placebo (p=0.020) in a 43-subject double-blind Phase 1b vitiligo study (32 FB102, 11 placebo). In the more severely affected subgroup (baseline FVASI ≥0.75), FB102 showed 43.2% mean improvement (p=0.006) with 58.8% achieving FVASI50 responder status. Statistical significance was reached by day 64 and persisted through week 24 post-treatment; 84% of treated subjects improved with 0% worsening, versus 27% of placebo subjects worsening. Safety profile remained mild-to-moderate with no severe adverse events.